You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行报告》里昂升翰森制药(03692.HK)目标价至29.55元 评级「跑赢大市」
阿思达克 09-02 12:48

里昂发表研究报告指,翰森制药(03692.HK)上半年收入按年增21.9%至45.99亿元人民币,毛利率受到「4+7带量集中采购」影响跌至91.7%,盈利则按年升24.3%至12.96亿元人民币,略低於该行全年预期。

不过该行指,由於公司今年将推出数个重要产品,包括:GLP-1及自主创新药氟马替尼(Flumatinib),预料2019年至2021年将可有强劲表现,分别录得盈利24.4亿元人民币、30.96亿元人民币及38.79亿元人民币。同时,将目标价由23.78元升至29.55元,维持评级「跑赢大市」。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account